EX-VIVO TUMOR STUDIES
Guiding cancer therapy.
Around 90% of drugs that look promising in in vivo trials end up failing in clinical settings; 0.02% of all drugs developed eventually end up on the market. At PharmaLegacy, we understand these numbers are intimidating. We aim at mitigating all risks your pipelines have, and improving these numbers. With our ex-vivo tumor study models, notably our tumor histopathology studies, 3D tumor tissue cultures and tumor microenvironment studies, we at PharmaLegacy are confident that we can take your pipelines from start to finish.
Put your trust in the right CRO. Put your trust in PharmaLegacy.
MODELS / SERVICES
Why do we need tumor tissue culture?
What is so good about mice-derived, 3D tumor culture?
Pharmalegacy’s Tissue Culture Platform
Readouts of Tumor Tissue Culture Platform
Best-In-Class Bioluminescence, Multispectral Fluorescence and Integrated X Optical Imaging Technology
Flexible Conversion of X Imaging in Mice or Rats
Committed to quality:
- Completed over 400 FDA / CFDA IND filings
- AAALAC accredited vivarium
- 24/7 access to PharmaLegacy representatives
- 380,000 square feet of facility space
Looking for a CRO that can deliver pipeline breakthroughs? Contact PharmaLegacy.
Providing Better Data for Critical Immuno-Oncology Pipeline Decisions
PharmaLegacy works to get you the answers you need with our wide selection of carefully developed in vivo and in vitro models. In this document, you’ll see a sample of the in vitro assays we run along with a sample of real-world data from them. See why over 700 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical pipeline decisions.